ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $124,862,422 | -13.0% | 5,991,479 | 0.0% | 4.21% | +19.8% |
| Q2 2023 | $143,495,922 | +27.3% | 5,991,479 | 0.0% | 3.52% | -3.2% |
| Q1 2023 | $112,759,635 | +18.2% | 5,991,479 | 0.0% | 3.63% | +25.1% |
| Q4 2022 | $95,384,346 | -2.7% | 5,991,479 | 0.0% | 2.90% | +0.3% |
| Q3 2022 | $98,021,000 | +16.1% | 5,991,479 | 0.0% | 2.89% | -0.7% |
| Q2 2022 | $84,420,000 | -41.8% | 5,991,479 | 0.0% | 2.91% | -35.8% |
| Q1 2022 | $145,114,000 | +103.1% | 5,991,479 | +95.8% | 4.54% | +99.4% |
| Q4 2021 | $71,434,000 | +988.4% | 3,060,593 | +2160.2% | 2.28% | +369.3% |
| Q2 2020 | $6,563,000 | -52.0% | 135,413 | -58.2% | 0.48% | -66.1% |
| Q1 2020 | $13,684,000 | -36.0% | 323,889 | -35.2% | 1.43% | -25.8% |
| Q4 2019 | $21,390,000 | – | 500,000 | – | 1.93% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |